Search
angiotensin II (Giapreza)
octapeptide; biologically active component of renin-angiotensin system; formed from angiotensin-I by action of angiotensin converting enzyme.
Function:
1) stimulates Na+ retention through adrenal formation of aldosterone
2) enhances blood vessel contraction
3) stimulates thirst through receptors in the brain
Pharmacology:
Indications:
- treatment of hypotension in patients in shock (Giapreza FDA-approved Dec 2017)
Dosage:
- 20 ng/kg/min IV by continuous infusion.
- titrate q5min by increments of up to 15 ng/kg/min prn to achieve or maintain target blood pressure
- not to exceed 80 ng/kg/min within 1st 3 hours
- maintenance: do not exceed 40 ng/kg/min
- doses as low as 1.25 ng/kg/min may be used
Monitor: blood pressure
Related
angiotensin-2 receptor
General
angiotensin
endocrine agent
Properties
COMPARTMENT: extracellular compartment
References
- FDA News Release. Dec 21, 2017
FDA approves drug to treat dangerously low blood pressure.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm590249.htm
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Khanna A, English SW, Wang XS et al
Angiotensin II for the Treatment of Vasodilatory Shock.
N Engl J Med. 2017 Aug 3;377(5):419-430. Epub 2017 May 21.
PMID: 28528561